Another strength of this study is the evaluation of the effect of naltrexone on several other measurements: schizophrenia symptoms, depression, dietary consumption, quality of life, cognitive functioning, physical activity, metabolism/inflammation markers: serum leptin, ghrelin, peptite YY, adinopectin, high sensitivity CRP, interleukin 6, interleukin-1B, interleukin-18 and tumor necrosis factor alpha. This evidence concerns the gene GHRL and depressive symptom measurement.